Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatment-naïve postmenopausal females

Annals of Pharmacotherapy

Volumn 47, Issue 1, 2013, Pages 29-34

  Hashem, Mohamed G ^a   Cleary, Kevin ^a   Fishman, Doris ^a   Nichols, Linda ^a   Khalid, Mona ^a  

^a Express Scripts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CELECOXIB; DEXTROPROPOXYPHENE; DULOXETINE; EXEMESTANE; GABAPENTIN; LETROZOLE; OPIATE; PREGABALIN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTHRALGIA; ARTICLE; CONCURRENT PRESCRIPTION ANTIARTHRALGIA PHARMACOTHERAPY; CONTROLLED STUDY; DRUG INDICATION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; ANALGESICS; AROMATASE INHIBITORS; ARTHRALGIA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDICATION ADHERENCE; POSTMENOPAUSE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84872981151     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R369     Document Type: Article

References (26)

1. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clini- cal Oncology Clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-3796.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Breast cancer. Version 3.2012. www.nccn.org/ professionals/physician_gls/pdf/breast.pdf (accessed 2012 Sept 17).
3. Miller WR, Hawkins RA, Forrest A P. Significance of aromatase activity in human breast cancer. Cancer Res 1982;42(8 suppl):3365s-3368s.
4. Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Der- matol 2001;45:S116-S124.
5. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007;16:223-234.
6. Sherwin BB. Hormones, mood, and cognitive functioning in post- menopausal women. Obstet Gynecol 1996;87:20S-26S.
7. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 2005;52:2594-2598.
8. Ho SC, Chan SG, Yip YB, et al. Menopausal symptoms and symptom clustering in Chinese women. Maturitas 1999;33:219-227.
9. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982-988.
10. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole fol- lowing tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271.
11. ATAC Trialists' Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
12. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of ex- emestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane study): a randomised controlled trial. Lancet 2007;369:559-570.
13. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamox- ifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008;26:1972-1979.
14. Donnellan P P, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia (letter). J Clin Oncol 2001;19:27-67.
15. Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early- stage breast cancer. J Clin Oncol 2012;30:936-942.
16. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the as- sociation between adherence to drug therapy and mortality. BMJ 2006; 333:15-20.
17. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
18. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-ad- herence to adjuvant hormonal therapy are associated with increased mortali- ty in women with breast cancer. Breast Cancer Res Treat 2011;126:529-537.
19. Cramer J, Roy A, Burrell A, et al. Medication compliance and persis- tence: terminology and definitions. Value Health 2008;11:44-47.
20. Motheral B. Persistency is the best measure of adherence. http://rxout- comesadviser.wordpress.com/2011/03/17/persistency-best-measure/ (ac- cessed 2012 Sept 17).
21. Throne C. Management of arthralgias associated with aromatase in- hibitor therapy. Curr Oncol 2007;14(suppl 1):S11-S19.
22. Coleman RE, Bolten WW, Lansdown M, et al. Aromatase inhibitor-in- duced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008;34:275-282.
23. Dent SF, Gaspo R, Kissner M, et al. Aromatase inhibitor therapy: toxici- ties and management strategies in the treatment of postmenopausal wom- en with hormone-sensitive early breast cancer. Breast Cancer Res Treat 2011;126:295-310.
24. Sedjo R, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011;125:191-200.
25. Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer treatment-asso- ciated bone loss and fractures among women with breast cancer receiv- ing aromatase inhibitors. Clin Breast Cancer 2006;7:127-132.
26. Muslimani A, Spiro T, Chaudhry A, et al. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to elimi- nating these symptoms? Clin Breast Cancer 2009;9:34-38.